Click here to get full coverage on Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term  Yahoo Finance

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance

Click here to get full coverage on UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates  Seeking Alpha

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha

Click here to get full coverage on $URGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman  PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

Click here to get full coverage on Notable Wednesday Option Activity: UTHR, URGN, DSGN - Nasdaq

Notable Wednesday Option Activity: UTHR, URGN, DSGN  Nasdaq

Notable Wednesday Option Activity: UTHR, URGN, DSGN - Nasdaq

Click here to get full coverage on Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC - MarketBeat

Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC  MarketBeat

Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC - MarketBeat

Click here to get full coverage on Trading Systems Reacting to (URGN) Volatility - Stock Traders Daily

Trading Systems Reacting to (URGN) Volatility  Stock Traders Daily

Trading Systems Reacting to (URGN) Volatility - Stock Traders Daily

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - Sahm

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected  Sahm

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - Sahm

Click here to get full coverage on Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on $URGN stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is down 10% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs - Yahoo Finance

UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs  Yahoo Finance

UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs - Yahoo Finance

Click here to get full coverage on Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

Click here to get full coverage on Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report - Yahoo Finance

Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report  Yahoo Finance

Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report - Yahoo Finance

Click here to get full coverage on Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results - Yahoo Finance

Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results  Yahoo Finance

Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Click here to get full coverage on Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance

Click here to get full coverage on Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN) - MarketBeat

Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN)  MarketBeat

Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN) - MarketBeat

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy? - MarketBeat

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy?  MarketBeat

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy? - MarketBeat

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages  MarketBeat

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN) - Seeking Alpha

UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN)  Seeking Alpha

UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com

Urogen Pharma (URGN) general counsel sells $29k in shares  Investing.com

Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

Click here to get full coverage on UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewswire

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum  GlobeNewswire

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewswire

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

Click here to get full coverage on Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily

Discipline and Rules-Based Execution in URGN Response  Stock Traders Daily

Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily

Click here to get full coverage on Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat

Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN  MarketBeat

Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on Urogen Pharma Ltd expected to post a loss of 69 cents a share - Earnings Preview - TradingView — Track All Markets

Urogen Pharma Ltd expected to post a loss of 69 cents a share - Earnings Preview  TradingView — Track All Markets

Urogen Pharma Ltd expected to post a loss of 69 cents a share - Earnings Preview - TradingView — Track All Markets

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (URGN) Movement - Stock Traders Daily

Avoiding Lag: Real-Time Signals in (URGN) Movement  Stock Traders Daily

Avoiding Lag: Real-Time Signals in (URGN) Movement - Stock Traders Daily

Click here to get full coverage on UroGen (NASDAQ: URGN) assigned permanent J Code J9282 for ZUSDURI, effective Jan 2026 - Stock Titan

UroGen (NASDAQ: URGN) assigned permanent J Code J9282 for ZUSDURI, effective Jan 2026  Stock Titan

UroGen (NASDAQ: URGN) assigned permanent J Code J9282 for ZUSDURI, effective Jan 2026 - Stock Titan

Click here to get full coverage on $URGN stock is up 11% today. Here's what we see in our data. - Nasdaq

$URGN stock is up 11% today. Here's what we see in our data.  Nasdaq

$URGN stock is up 11% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on UroGen Pharma (URGN) Reiterates Buy Rating with $40 Price Target | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Reiterates Buy Rating with $40 Price Target | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Reiterates Buy Rating with $40 Price Target | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)  simplywall.st

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Click here to get full coverage on URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)  Business Wire

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire

Click here to get full coverage on Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN - MarketBeat

Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN  MarketBeat

Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on UroGen (Nasdaq: URGN) gains FDA agreement on UGN-103 NDA; UTOPIA posts 77.8% CR - Stock Titan

UroGen (Nasdaq: URGN) gains FDA agreement on UGN-103 NDA; UTOPIA posts 77.8% CR  Stock Titan

UroGen (Nasdaq: URGN) gains FDA agreement on UGN-103 NDA; UTOPIA posts 77.8% CR - Stock Titan

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Click here to get full coverage on 3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends  MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Click here to get full coverage on UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ)  Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

Click here to get full coverage on UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN) - simplywall.st

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)  simplywall.st

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN) - simplywall.st

Click here to get full coverage on URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for - GlobeNewswire

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for  GlobeNewswire

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for - GlobeNewswire

Click here to get full coverage on UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout  S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

Click here to get full coverage on UroGen Pharma Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

UroGen Pharma Joins Rank Of Stocks With RS Ratings Over 90  Investor's Business Daily

UroGen Pharma Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Click here to get full coverage on UroGen Pharma stock jumps after positive Phase 3 trial results - Investing.com

UroGen Pharma stock jumps after positive Phase 3 trial results  Investing.com

UroGen Pharma stock jumps after positive Phase 3 trial results - Investing.com

Click here to get full coverage on UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09 - Seeking Alpha

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09  Seeking Alpha

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09 - Seeking Alpha

Click here to get full coverage on Cardinal Health (CAH) Acquires UroGen Pharma (URGN) for $1.9 Bil - GuruFocus

Cardinal Health (CAH) Acquires UroGen Pharma (URGN) for $1.9 Bil  GuruFocus

Cardinal Health (CAH) Acquires UroGen Pharma (URGN) for $1.9 Bil - GuruFocus

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat  Investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com

Click here to get full coverage on URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on UroGen Pharma CFO Degnan sells $37k in shares - Investing.com

UroGen Pharma CFO Degnan sells $37k in shares  Investing.com

UroGen Pharma CFO Degnan sells $37k in shares - Investing.com

Click here to get full coverage on UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference  GlobeNewswire

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire

Click here to get full coverage on URGN: Analyst Jason Kolbert Maintains Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

URGN: Analyst Jason Kolbert Maintains Buy Rating with $25 Price Target | URGN Stock News  GuruFocus

URGN: Analyst Jason Kolbert Maintains Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

Click here to get full coverage on Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛

Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $31  富途牛牛

Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛

Click here to get full coverage on Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q3 Revenue $27.5M, vs. FactSet Est of $32.5M - marketscreener.com

Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q3 Revenue $27.5M, vs. FactSet Est of $32.5M  marketscreener.com

Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q3 Revenue $27.5M, vs. FactSet Est of $32.5M - marketscreener.com

Click here to get full coverage on UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 - Yahoo Finance

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025  Yahoo Finance

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 - Yahoo Finance

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

Click here to get full coverage on URGN: UroGen Pharma Secures Permanent J Code for ZUSDURI - GuruFocus

URGN: UroGen Pharma Secures Permanent J Code for ZUSDURI  GuruFocus

URGN: UroGen Pharma Secures Permanent J Code for ZUSDURI - GuruFocus

Click here to get full coverage on UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds  GlobeNewswire

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Click here to get full coverage on UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)  Business Wire

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire

Click here to get full coverage on UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus

UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis  GuruFocus

UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus

Click here to get full coverage on Urogen Pharma’s chief medical officer sells $38,043 in shares - Investing.com

Urogen Pharma’s chief medical officer sells $38,043 in shares  Investing.com

Urogen Pharma’s chief medical officer sells $38,043 in shares - Investing.com

Click here to get full coverage on Urogen Pharma Ltd reports results for the quarter ended September 30 - Earnings Summary - TradingView — Track All Markets

Urogen Pharma Ltd reports results for the quarter ended September 30 - Earnings Summary  TradingView — Track All Markets

URGN

Price Chart

Key Statistics

Technicals

About URGN

Latest News

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha

$URGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers